Cargando…
Comparing pharmacologic measures of tenofovir exposure in a U.S. pre-exposure prophylaxis randomized trial
It is critical to assess adherence to pre-exposure prophylaxis (PrEP) in clinical trials. The relationship between pharmacokinetic measures of PrEP adherence and other adherence measures used in PrEP trials requires further characterization. Plasma, peripheral blood mononuclear cells (PBMCs), and ha...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5760024/ https://www.ncbi.nlm.nih.gov/pubmed/29315307 http://dx.doi.org/10.1371/journal.pone.0190118 |
_version_ | 1783291310889762816 |
---|---|
author | Baxi, Sanjiv M. Vittinghoff, Eric Bacchetti, Peter Huang, Yong Chillag, Kata Wiegand, Ryan Anderson, Peter L. Grant, Robert Greenblatt, Ruth M. Buchbinder, Susan Gandhi, Monica Liu, Albert Y. |
author_facet | Baxi, Sanjiv M. Vittinghoff, Eric Bacchetti, Peter Huang, Yong Chillag, Kata Wiegand, Ryan Anderson, Peter L. Grant, Robert Greenblatt, Ruth M. Buchbinder, Susan Gandhi, Monica Liu, Albert Y. |
author_sort | Baxi, Sanjiv M. |
collection | PubMed |
description | It is critical to assess adherence to pre-exposure prophylaxis (PrEP) in clinical trials. The relationship between pharmacokinetic measures of PrEP adherence and other adherence measures used in PrEP trials requires further characterization. Plasma, peripheral blood mononuclear cells (PBMCs), and hair samples were collected from 88 HIV-uninfected men who have sex with men in a placebo-controlled randomized PrEP trial; announced pill counts, medication electronic monitoring (MEMS), and self-report using visual analog scale (VAS) were also collected. Tenofovir (TFV or TFV-DP) in plasma, hair, and PBMCs were quantified. Proportions with drug detection, Spearman correlation coefficients, and univariate and multivariable regression models were used. Drug detection in plasma, PBMC, and hair samples was highly concordant with treatment arm assignment. TFV or TFV-DP levels were detected in most active-arm participants: 44/47 (94%) in plasma, 46/47 (98%) in hair, and 44/47 (94%) in PBMCs and in only 1/41 placebo arm participant. Correlation coefficients were r = 0.59 for plasma and PBMC, r = 0.34 for PBMC and hair and r = 0.36 for plasma and hair. MEMS and announced pill-counts were moderately correlated (r = 0.52) but less so with pharmacologic measures (range of r = 0.12 to 0.38). Self-reported adherence by visual analog scale demonstrated essentially no correlation with drug levels (r = 0.06 for hair, PBMC or plasma) and was a poor indicator of exposure to study product. Indices of drug exposure are important indicators in assessing adherence to PrEP; accounting for variability between measures may improve interpretation and use of adherence measures in future PrEP studies. CLINICAL TRIAL REGISTRATION: Clinical Trials.gov NCT00131677 |
format | Online Article Text |
id | pubmed-5760024 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-57600242018-01-22 Comparing pharmacologic measures of tenofovir exposure in a U.S. pre-exposure prophylaxis randomized trial Baxi, Sanjiv M. Vittinghoff, Eric Bacchetti, Peter Huang, Yong Chillag, Kata Wiegand, Ryan Anderson, Peter L. Grant, Robert Greenblatt, Ruth M. Buchbinder, Susan Gandhi, Monica Liu, Albert Y. PLoS One Research Article It is critical to assess adherence to pre-exposure prophylaxis (PrEP) in clinical trials. The relationship between pharmacokinetic measures of PrEP adherence and other adherence measures used in PrEP trials requires further characterization. Plasma, peripheral blood mononuclear cells (PBMCs), and hair samples were collected from 88 HIV-uninfected men who have sex with men in a placebo-controlled randomized PrEP trial; announced pill counts, medication electronic monitoring (MEMS), and self-report using visual analog scale (VAS) were also collected. Tenofovir (TFV or TFV-DP) in plasma, hair, and PBMCs were quantified. Proportions with drug detection, Spearman correlation coefficients, and univariate and multivariable regression models were used. Drug detection in plasma, PBMC, and hair samples was highly concordant with treatment arm assignment. TFV or TFV-DP levels were detected in most active-arm participants: 44/47 (94%) in plasma, 46/47 (98%) in hair, and 44/47 (94%) in PBMCs and in only 1/41 placebo arm participant. Correlation coefficients were r = 0.59 for plasma and PBMC, r = 0.34 for PBMC and hair and r = 0.36 for plasma and hair. MEMS and announced pill-counts were moderately correlated (r = 0.52) but less so with pharmacologic measures (range of r = 0.12 to 0.38). Self-reported adherence by visual analog scale demonstrated essentially no correlation with drug levels (r = 0.06 for hair, PBMC or plasma) and was a poor indicator of exposure to study product. Indices of drug exposure are important indicators in assessing adherence to PrEP; accounting for variability between measures may improve interpretation and use of adherence measures in future PrEP studies. CLINICAL TRIAL REGISTRATION: Clinical Trials.gov NCT00131677 Public Library of Science 2018-01-09 /pmc/articles/PMC5760024/ /pubmed/29315307 http://dx.doi.org/10.1371/journal.pone.0190118 Text en https://creativecommons.org/publicdomain/zero/1.0/ This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 (https://creativecommons.org/publicdomain/zero/1.0/) public domain dedication. |
spellingShingle | Research Article Baxi, Sanjiv M. Vittinghoff, Eric Bacchetti, Peter Huang, Yong Chillag, Kata Wiegand, Ryan Anderson, Peter L. Grant, Robert Greenblatt, Ruth M. Buchbinder, Susan Gandhi, Monica Liu, Albert Y. Comparing pharmacologic measures of tenofovir exposure in a U.S. pre-exposure prophylaxis randomized trial |
title | Comparing pharmacologic measures of tenofovir exposure in a U.S. pre-exposure prophylaxis randomized trial |
title_full | Comparing pharmacologic measures of tenofovir exposure in a U.S. pre-exposure prophylaxis randomized trial |
title_fullStr | Comparing pharmacologic measures of tenofovir exposure in a U.S. pre-exposure prophylaxis randomized trial |
title_full_unstemmed | Comparing pharmacologic measures of tenofovir exposure in a U.S. pre-exposure prophylaxis randomized trial |
title_short | Comparing pharmacologic measures of tenofovir exposure in a U.S. pre-exposure prophylaxis randomized trial |
title_sort | comparing pharmacologic measures of tenofovir exposure in a u.s. pre-exposure prophylaxis randomized trial |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5760024/ https://www.ncbi.nlm.nih.gov/pubmed/29315307 http://dx.doi.org/10.1371/journal.pone.0190118 |
work_keys_str_mv | AT baxisanjivm comparingpharmacologicmeasuresoftenofovirexposureinauspreexposureprophylaxisrandomizedtrial AT vittinghofferic comparingpharmacologicmeasuresoftenofovirexposureinauspreexposureprophylaxisrandomizedtrial AT bacchettipeter comparingpharmacologicmeasuresoftenofovirexposureinauspreexposureprophylaxisrandomizedtrial AT huangyong comparingpharmacologicmeasuresoftenofovirexposureinauspreexposureprophylaxisrandomizedtrial AT chillagkata comparingpharmacologicmeasuresoftenofovirexposureinauspreexposureprophylaxisrandomizedtrial AT wiegandryan comparingpharmacologicmeasuresoftenofovirexposureinauspreexposureprophylaxisrandomizedtrial AT andersonpeterl comparingpharmacologicmeasuresoftenofovirexposureinauspreexposureprophylaxisrandomizedtrial AT grantrobert comparingpharmacologicmeasuresoftenofovirexposureinauspreexposureprophylaxisrandomizedtrial AT greenblattruthm comparingpharmacologicmeasuresoftenofovirexposureinauspreexposureprophylaxisrandomizedtrial AT buchbindersusan comparingpharmacologicmeasuresoftenofovirexposureinauspreexposureprophylaxisrandomizedtrial AT gandhimonica comparingpharmacologicmeasuresoftenofovirexposureinauspreexposureprophylaxisrandomizedtrial AT liualberty comparingpharmacologicmeasuresoftenofovirexposureinauspreexposureprophylaxisrandomizedtrial |